证券代码：600873 证券简称：梅花生物 公告编号：2025-049 梅花生物科技集团股份有限公司 关于2025年半年度经营数据公告 公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据《上市公司行业信息披露指引第十四号—食品制造》第十四条相关规定， 现将梅花生物科技集团股份有限公司（以下简称"公司"）2025 年半年度经营 数据（未经审计）公告如下： 1、按产品分： | 产品类别 | 本期营业收入（万元） | | --- | --- | | 鲜味剂（谷氨酸钠、核苷酸） | 356,622.56 | | 饲料氨基酸（赖氨酸、苏氨酸、饲料级缬氨酸等） | 565,978.16 | | 医药氨基酸（谷氨酰胺、脯氨酸、异亮氨酸、鸟苷、腺苷等） | 24,734.04 | | 大原料副产品（肥料、蛋白粉、胚芽、玉米皮粉、饲料纤维等） | 188,930.22 | | 其他（黄原胶、海藻糖等） | 91,780.08 | | 合计 | 1,228,045.06 | 2、按销售模式分： 特此公告。 梅花生物科技集团股份有限公司董事会 ...

Investment Rating - The report suggests a positive outlook for the maternal and infant industry, driven by government policies aimed at encouraging childbirth and stimulating market growth [2][3]. Core Insights - The implementation of various supportive policies by the government is expected to boost the maternal and infant industry, with a projected increase in birth rates and consumer spending in this sector [6][9]. - The maternal and infant consumption market in China is anticipated to grow significantly, reaching approximately 76,299 billion yuan in 2024, with a potential increase to 89,149 billion yuan by 2027 [9][11]. - The report highlights the rapid development of the infant food market, with a compound annual growth rate (CAGR) of 8.9% from 2019 to 2024, leading to a market size of about 55.91 billion yuan in 2024 [25][29]. - The maternal and infant retail chain market is also expanding, with a projected growth from 587.4 billion yuan in 2019 to 906.2 billion yuan in 2024, reflecting a CAGR of 9.1% [32][34]. Summary by Sections Policy Impact - The Chinese government has introduced various policies to encourage childbirth, including subsidies and tax reductions, which are expected to stabilize and potentially increase the birth rate [6][7]. - The focus on modern parenting and quality of life among younger parents is driving demand for diverse maternal and infant products [6][9]. Market Growth - The maternal and infant consumption market is projected to grow to 76,299 billion yuan in 2024, marking a significant recovery in birth rates with 9.54 million births expected [9][11]. - The infant food market is experiencing rapid growth, with a projected market size of 55.91 billion yuan in 2024 and a CAGR of 8.9% from 2019 to 2024 [25][29]. Industry Segmentation - The report outlines the structure of the maternal and infant industry, which includes upstream food production, midstream manufacturing of products, and downstream retail channels [13][14]. - The dairy industry is also highlighted, with a projected market size of 5,216.70 billion yuan in 2024, despite a slight decline in milk production due to market imbalances [16][20]. Company Analysis - The report identifies key companies in the maternal and infant sector listed on the Beijing Stock Exchange, including Knight Dairy and Wuxi Jinghai, along with potential listings such as Southern Dairy and Ying's Holdings [44][45]. - The overall market capitalization of the consumer service sector on the Beijing Stock Exchange has increased, with a median market cap of 123.92 billion yuan [52][54].

2025年全球脯氨酸行业市场规模约5.6亿美元 中国市 场占据重要地位[图] 共研产业研究院通过对公开信息分析、业内资深人士和相关企业高管的深度访谈，以及分析师专业性判断 和评价撰写了《2025-2031年中国脯氨酸市场调查与投资潜力分析报告》。本报告为脯氨酸企业决策人及投 资者提供了重要参考依据。 为确保脯氨酸行业数据精准性以及内容的可参考价值，共研产业研究院团队通过上市公司年报、厂家调 研、经销商座谈、专家验证等多渠道开展数据采集工作，并运用共研自主建立的产业分析模型，结合市 场、行业和厂商进行深度剖析，能够反映当前市场现状、热点、动态及未来趋势，使从业者能够从多种维 度、多个侧面综合了解当前脯氨酸行业的发展态势。 脯氨酸是一种环状的亚氨基酸，它是蛋白质的组成成分之一，也是哺乳动物的非必需氨基酸和生糖氨基 酸。脯氨酸作为一种重要的氨基酸，在生物体内具有多种生物学功能和代谢途径。它在蛋白质结构、代谢 调节以及疾病治疗等方面都发挥着重要作用。 脯氨酸生物功能 | 脯氨酸在肽链中有 | 它可以作为蛋白质 | 脯氨酸生物功能 脯氨酸可以通过脯 氨酸羟化酶的作用 | 脯氨酸还可以作为 | | | --- | --- ...